1911579-04-8
Chemical Structure
GS-704277
- CAS No.: 1911579-04-8
- Formula:C15H19N6O8P
- Molecular Weight:442.32
IUPAC Name: ((((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)-L-alanine
InChIKey: IYHPTSNEWCZBDF-NIFWRESRSA-N
SMILES: OC([C@H](C)NP(OC[C@@H]1[C@@H](O)[C@@H](O)[C@@](C2=CC=C3N2N=CN=C3N)(C#N)O1)(O)=O)=O
Biological Activity: GS-704277 is an alanine metabolite of Remdesivir (HY-104077). GS-704277 is further hydrolyzed to GA-441524 (HY-103586) with antiviral activity. Remdesivir, a nucleoside analogue with effective antiviral activity, is highly effective in the control of SARS-CoV-2 (COVID-19) infection[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
GS-704277 | 98.77% | GS-704277 is an alanine metabolite of Remdesivir (HY-104077). GS-704277 is further hydrolyzed to GA-441524 (HY-103586) with antiviral activity. Remdesivir, a nucleoside analogue with effective antiviral activity, is highly effective in the control of SARS-CoV-2 (COVID-19) infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Eastman RT, et al. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19 [published correction appears in ACS Cent Sci. 2020 Jun 24;6(6):1009]. ACS Cent Sci. 2020;6(5):672-683. [Content Brief]
- [2]. Wang M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. [Content Brief]
- [3]. Yan VC, et al. Captisol and GS-704277, but Not GS-441524, Are Credible Mediators of Remdesivir's Nephrotoxicity. Antimicrob Agents Chemother. 2020 Nov 17;64(12):e01920-20. [Content Brief]
- [4]. Sullivan JT. Postmarketing pharmacovigilance: Remdesivir and cardiovascular events. Clin Transl Sci. 2022 Apr;15(4):813-815. [Content Brief]
- [5]. Prabha PK, et al. Can changing the prodrug moiety in remdesivir be a life-saving strategy in COVID-19 infection? Indian J Med Res. 2023 Jan;157(1):100-103. [Content Brief]
Keywords